MOUNTAIN VIEW, Calif., Sept. 29, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society, to be held October 1st to October 5th, 2011 in Orlando, Florida. The Obesity Society's Annual Scientific Meeting has grown to be one of the largest gatherings of obesity professionals worldwide.
The posters will be displayed in the Cypress Ballroom of the Orlando World Center Marriott on October 3, 2011 from 9:30 a.m. to 1:45 p.m. Eastern Time (ET) and from 3:00 p.m. to 6:30 p.m. ET. Authors will be available at the posters on October 3, 2011 from 12:30 p.m. to 1:30 p.m. ET.Title:
Weight Loss With Controlled-Release Phentermine/Topiramate is Associated With Significant Reductions in Use of Concomitant Medications for Cardiometabolic Diseases Over 108 WeeksAuthors:
W. Timothy Garvey, MD; Thomas Najarian, MD; Craig Peterson, MSPoster Number:
Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate Correlates With Improvements in Liver Function in Overweight/Obese Adults With Elevated Alanine AminotransferaseAuthors:
Samuel Klein, MD; Thomas Najarian, MD; Barbara Troupin, MD, MBA; Wesley W. Day, PhD Poster Number:
Severely Obese Adults Administered Controlled-Release Phentermine/Topiramate Maintained Their Weight Loss in the Second YearAuthors:
Kishore M. Gadde, MD; David B. Allison, PhD; Peter Y. Tam, MBA; Barbara Troupin, MD, MBAPoster Number:
593-PAbout QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlle
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved